Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Study Describes Evaluation of Cancer Biomarkers

Published: Wednesday, June 11, 2008
Last Updated: Thursday, June 12, 2008
Bookmark and Share
Bio-Rad researchers evaluated the Bio-Plex® suspension array system’s ability to detect the levels of nine biomarkers.

Bio-Rad Laboratories, Inc. has announced the availability of a technical note (tech note 5654A) describing the study of an evaluation of cancer biomarkers.

In the study, Bio-Rad researchers evaluated the Bio-Plex® suspension array system’s ability to detect the levels of nine biomarkers, which were selected for their potential clinical relevance to cancer development.

The nine biomarkers: angiopoietin-2 (Ang-2), VEGF, PDGF-BB, leptin, PECAM-1, IL-8, follistatin, HGF, and G-CSF were collected in sera from four different types of cancer patients.

Preliminary analysis of different cancer samples showed statistically significant elevation of eight of the nine biomarkers studied, suggesting the importance of these markers as key regulators of angiogenesis. The reduction of the levels of leptin and PECAM-1 also provided interesting insight into the modulation of these markers in associated cancers.

The study demonstrated that the Bio-Plex system is capable of measuring the levels of multiple targets simultaneously in less than two hours, using as little as 12.5 µl of serum, plasma, and other matrices. According to company, this feature can reduced the time and cost spent on preliminary screening of serum samples for biomarker profiling.

In addition, the assays used were proven to be specific, sensitive, and reproducible. The Bio-Plex system also provided a broad range for measurements, which could be utilized depending on specific sensitivity requirements.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad Receives Award for QX100 Droplet Digital PCR System
Company receives Frost & Sullivan 2012 North American Laboratory Researchers’ Choice: Future market leader of digital PCR technology award.
Thursday, March 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Case Study Demonstrates Importance of MIQE for qPCR Data Analysis
Published by Bio-Rad Laboratories, Inc. this case study demonstrates how real-time PCR can lead to erroneous conclusions if the key steps set out in the MIQE guidelines are not followed.
Friday, February 17, 2012
Bio-Rad Acquires QuantaLife and Digital PCR Technology
Bio-Rad purchases QuantaLife for $162 million in cash plus potential future milestone payments.
Friday, October 07, 2011
Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
Monday, August 04, 2008
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Scientific News
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
New Genetic Risk Factors for Myopia Discovered
Genes and environment determine short-sightedness.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!